L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 8.18 NOK -1.92%
Market Cap: 558.4m NOK

EV/EBIT
Enterprise Value to EBIT

-4.8
Current
-2.7
Median
4.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-4.8
=
Enterprise Value
437m NOK
/
EBIT
-90.7m NOK
EBIT Growth EV/EBIT to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBIT: 19.7
Negative Multiple: -4.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 132.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -545.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.7
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -330.1 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-30.1
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A